wordpress_test

Menu
Help your Prostate Cancer Patients

Dive back into life

with confidence.

Proven suppression.1

Flexible dosing.1

Decades of experience.1

scroll-icon

With over 4 million patient-years’ real-world experience

and proven efficacy and safety data from over 20 published clinical trials, you can be assured that ELIGARD™ will reliably suppress testosterone for as long as your patients need1-6

References
  1. ELIGARD SmPC. Latest version.
  2. Tolmar. PSUR. 2023. Data on File.
  3. Shore ND, et al. BJU Int. 2017;119:239–244.
  4. Perez-Marrero R, et al. Clin Ther. 2002;24:1902–1914.
  5. Chu FM, et al. J Urol. 2002;168:1199–1203.
  6. Crawford ED, et al. J Urol. 2006;175:533–536
recordati-white

This website is intended for healthcare professionals only.


ELIGARD (leuprorelin acetate) is indicated for the treatment of hormone dependent
advanced prostate cancer and for the treatment of high-risk localised and locally advanced
hormone dependent prostate cancer in combination with radiotherapy.1

GL-ELIGA-0020 | July 2025 © 2025 Recordati